Randomised trial of glutamine, selenium, or both, to supplement parenteral nutrition for critically ill patients
Top Cited Papers
Open Access
- 17 March 2011
- Vol. 342 (mar17 2) , d1542
- https://doi.org/10.1136/bmj.d1542
Abstract
Objective To determine whether inclusion of glutamine, selenium, or both in a standard isonitrogenous, isocaloric preparation of parenteral nutrition influenced new infections and mortality among critically ill patients. Design Randomised, double blinded, factorial, controlled trial. Setting Level 2 and 3 (or combined) critical care units in Scotland. All 22 units were invited, and 10 participated. Participants 502 adults in intensive care units and high dependency units for ≥48 hours, with gastrointestinal failure and requiring parenteral nutrition. Interventions Parenteral glutamine (20.2 g/day) or selenium (500 μg/day), or both, for up to seven days. Main outcome measures Primary outcomes were participants with new infections in the first 14 days and mortality. An intention to treat analysis and a prespecified analysis of patients who received ≥5 days of the trial intervention are presented. Secondary outcomes included critical care unit and acute hospital lengths of stay, days of antibiotic use, and modified SOFA (Sepsis-related Organ Failure Assessment) score. Results Selenium supplementation did not significantly affect patients developing a new infection (126/251 v 139/251, odds ratio 0.81 (95% CI 0.57 to 1.15)), except for those who had received ≥5 days of supplementation (odds ratio 0.53 (0.30 to 0.93)). There was no overall effect of glutamine on new infections (134/250 v 131/252, odds ratio 1.07 (0.75 to 1.53)), even if patients received ≥5 days of supplementation (odds ratio 0.99 (0.56 to 1.75)). Six month mortality was not significantly different for selenium (107/251 v 114/251, odds ratio 0.89 (0.62 to 1.29)) or glutamine (115/250 v 106/252, 1.18 (0.82 to 1.70)). Length of stay, days of antibiotic use, and modified SOFA score were not significantly affected by selenium or glutamine supplementation. Conclusions The primary (intention to treat) analysis showed no effect on new infections or on mortality when parenteral nutrition was supplemented with glutamine or selenium. Patients who received parenteral nutrition supplemented with selenium for ≥5 days did show a reduction in new infections. This finding requires confirmation. Trial registration Current Controlled Trials ISRCTN87144826This publication has 20 references indexed in Scilit:
- Early enteral nutrition in the ICUIntensive Care Medicine, 2010
- Parenteral Nutrition in the Critically Ill PatientNew England Journal of Medicine, 2009
- Randomised trial of glutamine and selenium supplemented parenteral nutrition for critically ill patients. Protocol Version 9, 19 February 2007 known as SIGNET (Scottish Intensive care Glutamine or seleNium Evaluative Trial)Trials, 2007
- A.S.P.E.N. Statement on Parenteral Nutrition StandardizationJournal of Parenteral and Enteral Nutrition, 2007
- Optimizing the Dose of Glutamine Dipeptides and Antioxidants in Critically Ill Patients: A Phase I Dose‐Finding StudyJournal of Parenteral and Enteral Nutrition, 2007
- Selenium supplementation in critically ill patients: can too much of a good thing be a bad thing?Critical Care, 2007
- ESPEN Guidelines on Enteral Nutrition: Intensive careClinical Nutrition, 2006
- A Review of the True Methodological Quality of Nutritional Support Trials Conducted in the Critically Ill: Time for ImprovementAnesthesia & Analgesia, 2005
- Is intent‐to‐treat analysis always (ever) enough?British Journal of Clinical Pharmacology, 2002
- Requirements for providing optimal nutrition care: passion, evidence, and compassion‐‐presidential address to the 24th Clinical Congress, January 24, 2000Journal of Parenteral and Enteral Nutrition, 2002